rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2025-331-337rsp-3779Research ArticleПЕРЕДОВАЯLEADING ARTICLEМультиморбидность и плейотропные эффекты базисных препаратов, применяемых для лечения остеоартритаMultimorbidity and pleiotropic effects of basic drugs used for the treatment of osteoarthritishttps://orcid.org/0000-0001-7017-0898АлексееваЛ. И.AlekseevaL. I.

Алексеева Людмила Ивановна

115522, Москва, Каширское шоссе, 34а; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

Liudmila I. Alekseeva

115522, Moscow, Kashirskoye Highway, 34A; 125993, Moscow, Barrikadnaya str., 2/1, building 1

dr.alekseeva@gmail.comhttps://orcid.org/0000-0002-5804-4298РаскинаТ. А.RaskinaT. A.

650056, Кемерово, ул. Ворошилова, 22а

Tatiana A. Raskina

650056, Kemerovo, Voroshilova str., 22A

https://orcid.org/0000-0001-8218-3223ТаскинаЕ. А.TaskinaE. A.

115522, Москва, Каширское шоссе, 34а

Elena A. Taskina

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34а; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

Aleksander M. Lila

115522, Moscow, Kashirskoye Highway, 34A; 125993, Moscow, Barrikadnaya str., 2/1, building 1

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а

Evgeny L. Nasonov

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава РоссииРоссияKemerovo State Medical AcademyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202531082025634331337Copyright © Алексеева Л.И., Раскина Т.А., Таскина Е.А., Лила А.М., Насонов Е.Л., 20252025Алексеева Л.И., Раскина Т.А., Таскина Е.А., Лила А.М., Насонов Е.Л.Alekseeva L.I., Raskina T.A., Taskina E.A., Lila A.M., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3779

Данный обзор систематизирует современные данные о взаимосвязи остеоартрита (ОА) и коморбидных состояний, демонстрируя их взаимное негативное влияние. Особое внимание уделено базисным препаратам, в частности кристаллическому глюкозамину – сульфату, который обладает позитивными плейотропными эффектами и оказывает влияние не только на ОА, но и на сопутствующие заболевания. Продемонстрирован его потенциал в улучшении кардиометаболического статуса, микробиоты кишечника; снижении рисков нарушений углеводного обмена, подагры, деменции и смертности.

This review systematizes current data on the relationship between osteoarthritis (OA) and comorbid conditions, demonstrating their mutual negative influence. Particular attention is paid to basic drugs, in particular crystalline glucosamine sulfate, which have positive pleiotropic effects and affect not only OA, but also comorbidities. Its potential is demonstrated in improving cardiometabolic status, intestinal microbiota; reducing the risks of carbohydrate metabolism disorders, gout, dementia and mortality.

мультиморбидностьостеоартритплейотропные эффектыSYSADOAглюкозаминmultimorbidityosteoarthritispleiotropic effectsSYSADOAglucosamineИсследование не имело спонсорской поддержкиReferencesHunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: A Lancet Commission. Lancet. 2020;396(10264):1711-1712. doi: 10.1016/S0140-6736(20)32230-3Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: A Lancet Commission. Lancet. 2020;396(10264):1711-1712. doi: 10.1016/S0140-6736(20)32230-3GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990– 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. doi: 10.1016/S01406736(20)30925-9GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990– 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. doi: 10.1016/S01406736(20)30925-9Алексеева ЛИ, Таскина ЕА, Кашеварова НГ. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение. Современная ревматология. 2019;13(2):9-21. doi: 10.14412/1996-7012-2019-2-9-21Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis: epidemiology, classification, risk factors, al presentation, diagnosis, and treatment. Journal. 2019;13(2):9-21 (In Russ.). doi: 10.14412/1995-4484-2009-136Галушко ЕА, Большакова ТЮ, Виноградова ИБ, Иванова ОН, Лесняк ОМ, Меньшикова ЛВ, и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практическая ревматология. 2009;47(1):11-17. doi: 10.14412/1995-4484-2009-136Galushko EA, Bolshakova TY, Vinogradova IB, Ivanova ON, Lesnyak OM, Menshikova LV, et al. Structure of rheumatic diseases among adult population of Russia according to data of an epidemiological study (preliminary results). NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2009;47(1):11-17 (In Russ.)]. doi: 10.14412/1995-4484-2009-136Kovari E, Kaposi A, Bekes G, Kiss Z, Kurucz R, Mandl P, et al. Comorbidity clusters in generalized osteoarthritis among female patients: A cross-sectional study. Semin Arthritis Rheum. 2020;50(2):183-191. doi: 10.1016/j.semarthrit.2019.09.001Kovari E, Kaposi A, Bekes G, Kiss Z, Kurucz R, Mandl P, et al. Comorbidity clusters in generalized osteoarthritis among female patients: A cross-sectional study. Semin Arthritis Rheum. 2020;50(2):183-191. doi: 10.1016/j.semarthrit.2019.09.001Swain S, Sarmanova A, Coupland C, Doherty M, Zhang W. Comorbidities in Osteoarthritis: A systematic review and meta-analysis of observational studies. Arthritis Care Res. 2020;72(7):991-1000. doi: 10.1002/acr.24008Swain S, Sarmanova A, Coupland C, Doherty M, Zhang W. Comorbidities in Osteoarthritis: A systematic review and meta-analysis of observational studies. Arthritis Care Res. 2020;72(7):991-1000. doi: 10.1002/acr.24008Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4Leyland KM, Gates LS, Sanchez-Santos MT, Nevitt MC, Felson D, Jones G, et al.; PCCOA Steering Committee. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: An international meta-analysis of individual participantlevel data. Aging Clin Exp Res. 2021;33(3):529-545. doi: 10.1007/s40520-020-01762-2Leyland KM, Gates LS, Sanchez-Santos MT, Nevitt MC, Felson D, Jones G, et al.; PCCOA Steering Committee. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: An international meta-analysis of individual participantlevel data. Aging Clin Exp Res. 2021;33(3):529-545. doi: 10.1007/s40520-020-01762-2Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: Population based cohort study. BMJ. 2011;342:d1165. doi: 10.1136/bmj.d1165Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: Population based cohort study. BMJ. 2011;342:d1165. doi: 10.1136/bmj.d1165Wang H, Bai J, He B, Hu X, Liu D. Osteoarthritis and the risk of cardiovascular disease: A meta-analysis of observational studies. Sci Rep. 2016;6:39672. doi: 10.1038/srep39672Wang H, Bai J, He B, Hu X, Liu D. Osteoarthritis and the risk of cardiovascular disease: A meta-analysis of observational studies. Sci Rep. 2016;6:39672. doi: 10.1038/srep39672Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship between osteoarthritis and cardiovascular disease in a population health survey: A cross-sectional study. BMJ Open. 2013;3(5):e002624. doi: 10.1136/bmjopen-2013-002624Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship between osteoarthritis and cardiovascular disease in a population health survey: A cross-sectional study. BMJ Open. 2013;3(5):e002624. doi: 10.1136/bmjopen-2013-002624Mathieu S, Couderc M, Tournadre A, Soubrier M. Cardiovascular profile in osteoarthritis: A meta-analysis of cardiovascular events and risk factors. Joint Bone Spine. 2019;86(6):679-684. doi: 10.1016/j.jbspin.2019.06.013Mathieu S, Couderc M, Tournadre A, Soubrier M. Cardiovascular profile in osteoarthritis: A meta-analysis of cardiovascular events and risk factors. Joint Bone Spine. 2019;86(6):679-684. doi: 10.1016/j.jbspin.2019.06.013Macêdo MB, Santos VMOS, Pereira RMR, Fuller R. Association between osteoarthritis and atherosclerosis: A systematic review and meta-analysis. Exp Gerontol. 2022;161:111734. doi: 10.1016/j.exger.2022.111734Macêdo MB, Santos VMOS, Pereira RMR, Fuller R. Association between osteoarthritis and atherosclerosis: A systematic review and meta-analysis. Exp Gerontol. 2022;161:111734. doi: 10.1016/j.exger.2022.111734Xie Y, Zhou W, Zhong Z, Zhao Z, Yu H, Huang Y, et al. Metabolic syndrome, hypertension, and hyperglycemia were positively associated with knee osteoarthritis, while dyslipidemia showed no association with knee osteoarthritis. Clin Rheumatol. 2021;40(2):711-724. doi: 10.1007/s10067-020-05216-yXie Y, Zhou W, Zhong Z, Zhao Z, Yu H, Huang Y, et al. Metabolic syndrome, hypertension, and hyperglycemia were positively associated with knee osteoarthritis, while dyslipidemia showed no association with knee osteoarthritis. Clin Rheumatol. 2021;40(2):711-724. doi: 10.1007/s10067-020-05216-yKing KB, Rosenthal AK. The adverse effects of diabetes on osteoarthritis: Update on clinical evidence and molecular mechanisms. Osteoarthritis Cartilage. 2015;23(6):841-850. doi: 10.1016/j.joca.2015.03.031King KB, Rosenthal AK. The adverse effects of diabetes on osteoarthritis: Update on clinical evidence and molecular mechanisms. Osteoarthritis Cartilage. 2015;23(6):841-850. doi: 10.1016/j.joca.2015.03.031Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus and osteoarthritis: Systematic literature review and meta-analysis. RMD Open. 2015;1(1):e000077. doi: 10.1136/rmdopen-2015-000077Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus and osteoarthritis: Systematic literature review and meta-analysis. RMD Open. 2015;1(1):e000077. doi: 10.1136/rmdopen-2015-000077Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, et al. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2017;12:735-744. doi: 10.2147/COPD.S112256Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, et al. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2017;12:735-744. doi: 10.2147/COPD.S112256Huang SW, Wang WT, Chou LC, Liao CD, Liou TH, Lin HW. Osteoarthritis increases the risk of dementia: A nationwide cohort study in Taiwan. Sci Rep. 2015;5:10145. doi: 10.1038/srep10145Huang SW, Wang WT, Chou LC, Liao CD, Liou TH, Lin HW. Osteoarthritis increases the risk of dementia: A nationwide cohort study in Taiwan. Sci Rep. 2015;5:10145. doi: 10.1038/srep10145Ryu E, Chamberlain AM, Pendegraft RS, Petterson TM, Bobo WV, Pathak J. Quantifying the impact of chronic conditions on a diagnosis of major depressive disorder in adults: A cohort study using linked electronic medical records. BMC Psychiatry. 2016;16:114. doi: 10.1186/s12888-016-0821-xRyu E, Chamberlain AM, Pendegraft RS, Petterson TM, Bobo WV, Pathak J. Quantifying the impact of chronic conditions on a diagnosis of major depressive disorder in adults: A cohort study using linked electronic medical records. BMC Psychiatry. 2016;16:114. doi: 10.1186/s12888-016-0821-xLazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 2018;9:1830. doi: 10.3389/fimmu.2018.01830Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 2018;9:1830. doi: 10.3389/fimmu.2018.01830Favazzo LJ, Hendesi H, Villani DA, Soniwala S, Dar QA, Schott EM, et al. The gut microbiome-joint connection: Implications in osteoarthritis. Curr Opin Rheumatol. 2020;32(1):92-101. doi: 10.1097/BOR.0000000000000681Favazzo LJ, Hendesi H, Villani DA, Soniwala S, Dar QA, Schott EM, et al. The gut microbiome-joint connection: Implications in osteoarthritis. Curr Opin Rheumatol. 2020;32(1):92-101. doi: 10.1097/BOR.0000000000000681Schott EM, Farnsworth CW, Grier A, Lillis JA, Soniwala S, Dadourian GH, et al. Targeting the gut microbiome to treat the osteoarthritis of obesity. JCI Insight. 2018;3(8):e95997. doi: 10.1172/jci.insight.95997Schott EM, Farnsworth CW, Grier A, Lillis JA, Soniwala S, Dadourian GH, et al. Targeting the gut microbiome to treat the osteoarthritis of obesity. JCI Insight. 2018;3(8):e95997. doi: 10.1172/jci.insight.95997Griffin TM, Huebner JL, Kraus VB, Yan Z, Guilak F. Induction of osteoarthritis and metabolic inflammation by a very high-fat diet in mice: Effects of short-term exercise. Arthritis Rheum. 2012;64(2):443-453. doi: 10.1002/art.33332Griffin TM, Huebner JL, Kraus VB, Yan Z, Guilak F. Induction of osteoarthritis and metabolic inflammation by a very high-fat diet in mice: Effects of short-term exercise. Arthritis Rheum. 2012;64(2):443-453. doi: 10.1002/art.33332Yusuf E, Nelissen RG, Ioan-Facsinay A, Stojanovic-Susulic V, DeGroot J, van Osch G, et al. Association between weight or body mass index and hand osteoarthritis: A systematic review. Ann Rheum Dis. 2010;69(4):761-765. doi: 10.1136/ard.2008.106930Yusuf E, Nelissen RG, Ioan-Facsinay A, Stojanovic-Susulic V, DeGroot J, van Osch G, et al. Association between weight or body mass index and hand osteoarthritis: A systematic review. Ann Rheum Dis. 2010;69(4):761-765. doi: 10.1136/ard.2008.106930Boer CG, Radjabzadeh D, Uitterlinden AG, Kraaij R, van Meurs JB. The role of the gut microbiome in osteoarthritis and joint pain. Osteoarthr. Cartil. 2017;25:S10. doi: 10.1016/j.joca.2017.02.033Boer CG, Radjabzadeh D, Uitterlinden AG, Kraaij R, van Meurs JB. The role of the gut microbiome in osteoarthritis and joint pain. Osteoarthr. Cartil. 2017;25:S10. doi: 10.1016/j.joca.2017.02.033Coulson S, Butt H, Vecchio P, Gramotnev H, Vitetta L. Greenlipped mussel extract (Perna canaliculus) and glucosamine sulphate in patients with knee osteoarthritis: Therapeutic efficacy and effects on gastrointestinal microbiota profiles. Inflammopharmacology. 2013;21(1):79-90. doi: 10.1007/s10787-012-0146-4Coulson S, Butt H, Vecchio P, Gramotnev H, Vitetta L. Greenlipped mussel extract (Perna canaliculus) and glucosamine sulphate in patients with knee osteoarthritis: Therapeutic efficacy and effects on gastrointestinal microbiota profiles. Inflammopharmacology. 2013;21(1):79-90. doi: 10.1007/s10787-012-0146-4Wang X, Hunter D, Xu J, Ding C. Metabolic triggered inflammation in osteoarthritis. Osteoarthritis Cartilage. 2015;23(1):22-30. doi: 10.1016/j.joca.2014.10.002Wang X, Hunter D, Xu J, Ding C. Metabolic triggered inflammation in osteoarthritis. Osteoarthritis Cartilage. 2015;23(1):22-30. doi: 10.1016/j.joca.2014.10.002Liu Y, Ding W, Wang HL, Dai LL, Zong WH, Wang YZ, et al. Gut microbiota and obesity-associated osteoarthritis. Osteoarthritis Cartilage. 2019;27(9):1257-1265. doi: 10.1016/j.joca.2019.05.009Liu Y, Ding W, Wang HL, Dai LL, Zong WH, Wang YZ, et al. Gut microbiota and obesity-associated osteoarthritis. Osteoarthritis Cartilage. 2019;27(9):1257-1265. doi: 10.1016/j.joca.2019.05.009Wang J, Gu X, Yang J, Wei Y, Zhao Y. Gut microbiota dysbiosis and increased plasma LPS and TMAO levels in patients with preeclampsia. Front Cell Infect Microbiol. 2019;9:409. doi: 10.3389/fcimb.2019.00409Wang J, Gu X, Yang J, Wei Y, Zhao Y. Gut microbiota dysbiosis and increased plasma LPS and TMAO levels in patients with preeclampsia. Front Cell Infect Microbiol. 2019;9:409. doi: 10.3389/fcimb.2019.00409Hao X, Shang X, Liu J, Chi R, Zhang J, Xu T. The gut microbiota in osteoarthritis: Where do we stand and what can we do? Arthritis Res Ther. 2021;23(1):42. doi: 10.1186/s13075-021-02427-9Hao X, Shang X, Liu J, Chi R, Zhang J, Xu T. The gut microbiota in osteoarthritis: Where do we stand and what can we do? Arthritis Res Ther. 2021;23(1):42. doi: 10.1186/s13075-021-02427-9Boutagy NE, McMillan RP, Frisard MI, Hulver MW. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie. 2016;124:11-20. doi: 10.1016/j.biochi.2015.06.020Boutagy NE, McMillan RP, Frisard MI, Hulver MW. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie. 2016;124:11-20. doi: 10.1016/j.biochi.2015.06.020Berenbaum F. Deep phenotyping of osteoarthritis: A step forward. Ann Rheum Dis. 2019;78(1):3-5. doi: 10.1136/annrheumdis-2018-213864Berenbaum F. Deep phenotyping of osteoarthritis: A step forward. Ann Rheum Dis. 2019;78(1):3-5. doi: 10.1136/annrheumdis-2018-213864Chadha R. Revealed aspect of metabolic osteoarthritis. J Orthop. 2016;13(4):347-351. doi: 10.1016/j.jor.2016.06.029Chadha R. Revealed aspect of metabolic osteoarthritis. J Orthop. 2016;13(4):347-351. doi: 10.1016/j.jor.2016.06.029Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease? Joint Bone Spine. 2013;80(6):568-573. doi: 10.1016/j.jbspin.2013.09.007Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease? Joint Bone Spine. 2013;80(6):568-573. doi: 10.1016/j.jbspin.2013.09.007Berenbaum F, Griffin TM, Liu-Bryan R. Review: Metabolic regulation of inflammation in osteoarthritis. Arthritis Rheumatol. 2017;69(1):9-21. doi: 10.1002/art.39842Berenbaum F, Griffin TM, Liu-Bryan R. Review: Metabolic regulation of inflammation in osteoarthritis. Arthritis Rheumatol. 2017;69(1):9-21. doi: 10.1002/art.39842Turroni S, Pedersini P, Villafañe JH. The human gut microbiome and its relationship with osteoarthritis pain. Pain Med. 2021;22(7):1467-1469. doi: 10.1093/pm/pnaa422Turroni S, Pedersini P, Villafañe JH. The human gut microbiome and its relationship with osteoarthritis pain. Pain Med. 2021;22(7):1467-1469. doi: 10.1093/pm/pnaa422Алексеева ЛИ, Лила АМ. Базисная терапия остеоартрита: современный взгляд на применение препаратов глюкозамина и хондроитина. Современная ревматология. 2021;15(2):112119. doi: 10.14412/1996-7012-2021-2-112-119Alekseeva LI, Lila AM. Osteoarthritis background therapy: Current view on the glucosamine and chondroitin therapy. Modern Rheumatology Journal. 2021;15(2):112-119 (In Russ.). doi: 10.14412/1996-7012-2021-2-112-119Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2005(2):CD002946. doi: 10.1002/14651858.CD002946.pub2Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2005(2):CD002946. doi: 10.1002/14651858.CD002946.pub2Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: A meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken). 2014;66(12):1844-1855. doi: 10.1002/acr.22376Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: A meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken). 2014;66(12):1844-1855. doi: 10.1002/acr.22376Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, et al. Association of pharmacological treatments with longterm pain control in patients with knee osteoarthritis: A systematic review and meta-analysis. JAMA. 2018;320(24):2564-2579. doi: 10.1001/jama.2018.19319Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, et al. Association of pharmacological treatments with longterm pain control in patients with knee osteoarthritis: A systematic review and meta-analysis. JAMA. 2018;320(24):2564-2579. doi: 10.1001/jama.2018.19319Beaudart C, Lengelé L, Leclercq V, Geerinck A, Sanchez-Rodriguez D, Bruyère O, et al. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: A systematic review and a network meta-analysis with a 6-month time horizon. Drugs. 2020;80(18):1947-1959. doi: 10.1007/s40265-020-01423-8Beaudart C, Lengelé L, Leclercq V, Geerinck A, Sanchez-Rodriguez D, Bruyère O, et al. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: A systematic review and a network meta-analysis with a 6-month time horizon. Drugs. 2020;80(18):1947-1959. doi: 10.1007/s40265-020-01423-8Филатова ЮС, Яльцева НВ, Леонтьева ЕА. Плейотропные эффекты терапии остеоартрита. Медицинский совет. 2024;18(22):96-104. doi: 10.21518/ms2024-53Filatova YS, Yaltseva NV, Leontieva EA. Pleiotropic effects of osteoarthritis therapy. Medical Council. 2024;(22):96-104 (In Russ.). doi: 10.21518/ms2024-53Sibbritt D, Adams J, Lui CW, Broom A, Wardle J. Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PLoS One. 2012;7:e41540. doi: 10.1371/journal.pone.0041540Sibbritt D, Adams J, Lui CW, Broom A, Wardle J. Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PLoS One. 2012;7:e41540. doi: 10.1371/journal.pone.0041540Bell GA, Kantor ED, Lampe JW, Shen DD, White E. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012;27:593-603. doi: 10.1007/s10654-012-9714-6Bell GA, Kantor ED, Lampe JW, Shen DD, White E. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012;27:593-603. doi: 10.1007/s10654-012-9714-6Weimer S, Priebs J, Kuhlow D, Groth M, Priebe S, Mansfeld J, et al. D-glucosamine supplementation extends life span of nematodes and of ageing mice. Nat Commun. 2014;5:3563. doi: 10.1038/ncomms4563Weimer S, Priebs J, Kuhlow D, Groth M, Priebe S, Mansfeld J, et al. D-glucosamine supplementation extends life span of nematodes and of ageing mice. Nat Commun. 2014;5:3563. doi: 10.1038/ncomms4563Bazzano LA, Hu T, Reynolds K, Yao L, Bunol C, Liu Y, et al. Effects of low-carbohydrate and low-fat diets: A randomized trial. Ann Intern Med. 2014;161(5):309-318. doi: 10.7326/M14-0180Bazzano LA, Hu T, Reynolds K, Yao L, Bunol C, Liu Y, et al. Effects of low-carbohydrate and low-fat diets: A randomized trial. Ann Intern Med. 2014;161(5):309-318. doi: 10.7326/M14-0180Yao D, Xu L, Xu O, Li R, Chen M, Shen H, et al. O-linked β-N acetylglucosamine modification of A20 enhances the inhibition of NF-κB (nuclear factor-κB) activation and elicits vascular protection after acute endoluminal arterial injury. Arterioscler Thromb Vasc Biol. 2018;38(6):1309-1320. doi: 10.1161/ATVBAHA.117.310468Yao D, Xu L, Xu O, Li R, Chen M, Shen H, et al. O-linked β-N acetylglucosamine modification of A20 enhances the inhibition of NF-κB (nuclear factor-κB) activation and elicits vascular protection after acute endoluminal arterial injury. Arterioscler Thromb Vasc Biol. 2018;38(6):1309-1320. doi: 10.1161/ATVBAHA.117.310468Ma H, Li X, Sun D, Zhou T, Ley SH, Gustat J, et al. Association of habitual glucosamine use with risk of cardiovascular disease: Prospective study in UK Biobank. BMJ. 2019;365:l1628. doi: 10.1136/bmj.l1628Ma H, Li X, Sun D, Zhou T, Ley SH, Gustat J, et al. Association of habitual glucosamine use with risk of cardiovascular disease: Prospective study in UK Biobank. BMJ. 2019;365:l1628. doi: 10.1136/bmj.l1628Patti ME, Virkamäki A, Landaker EJ, Kahn CR, Yki-Järvinen H. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Diabetes. 1999;48(8):1562-1571. doi: 10.2337/diabetes.48.8.1562Patti ME, Virkamäki A, Landaker EJ, Kahn CR, Yki-Järvinen H. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Diabetes. 1999;48(8):1562-1571. doi: 10.2337/diabetes.48.8.1562Yomogida S, Hua J, Sakamoto K, Nagaoka I. Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-alpha-stimulated human colonic epithelial HT-29 cells. Int J Mol Med. 2008;22(2):205-211.Yomogida S, Hua J, Sakamoto K, Nagaoka I. Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-alpha-stimulated human colonic epithelial HT-29 cells. Int J Mol Med. 2008;22(2):205-211.Azuma K, Osaki T, Wakuda T, Tsuka T, Imagawa T, Okamoto Y, et al. Suppressive effects of N-acetyl-D-glucosamine on rheumatoid arthritis mouse models. Inflammation. 2012;35(4):1462-1465. doi: 10.1007/s10753-012-9459-0Azuma K, Osaki T, Wakuda T, Tsuka T, Imagawa T, Okamoto Y, et al. Suppressive effects of N-acetyl-D-glucosamine on rheumatoid arthritis mouse models. Inflammation. 2012;35(4):1462-1465. doi: 10.1007/s10753-012-9459-0Hu FB, Stampfer MJ. Is type 2 diabetes mellitus a vascular condition? Arterioscler Thromb Vasc Biol. 2003;23(10):1715-1716. doi: 10.1161/01.ATV.0000094360.38911.71Hu FB, Stampfer MJ. Is type 2 diabetes mellitus a vascular condition? Arterioscler Thromb Vasc Biol. 2003;23(10):1715-1716. doi: 10.1161/01.ATV.0000094360.38911.71Ma H, Li X, Zhou T, Sun D, Liang Z, Li Y, et al. Glucosamine use, inflammation, and genetic susceptibility, and incidence of type 2 diabetes: A prospective study in UK biobank. Diabetes Care. 2020;43(4):719-725. doi: 10.2337/dc19-1836Ma H, Li X, Zhou T, Sun D, Liang Z, Li Y, et al. Glucosamine use, inflammation, and genetic susceptibility, and incidence of type 2 diabetes: A prospective study in UK biobank. Diabetes Care. 2020;43(4):719-725. doi: 10.2337/dc19-1836Liu M, Ye Z, Zhang Y, Yang S, Wu Q, Zhou C, et al. Associations of habitual glucosamine supplementation with incident gout: A large population based cohort study. Biol Sex Differ. 2022;13(1):52. doi: 10.1186/s13293-022-00461-zLiu M, Ye Z, Zhang Y, Yang S, Wu Q, Zhou C, et al. Associations of habitual glucosamine supplementation with incident gout: A large population based cohort study. Biol Sex Differ. 2022;13(1):52. doi: 10.1186/s13293-022-00461-zLi G, Zhang X, Liu Y, Zhang J, Li L, Huang X, et al. Relationship between glucosamine use and the risk of lung cancer: Data from a nationwide prospective cohort study. Eur Respir J. 2022;59(3):2101399. doi: 10.1183/13993003.01399-2021Li G, Zhang X, Liu Y, Zhang J, Li L, Huang X, et al. Relationship between glucosamine use and the risk of lung cancer: Data from a nationwide prospective cohort study. Eur Respir J. 2022;59(3):2101399. doi: 10.1183/13993003.01399-2021Zheng J, Ni C, Zhang Y, Huang J, Hukportie DN, Liang B, et al. Association of regular glucosamine use with incident dementia: Evidence from a longitudinal cohort and Mendelian randomization study. BMC Med. 2023;21(1):114. doi: 10.1186/s12916-023-02816-8Zheng J, Ni C, Zhang Y, Huang J, Hukportie DN, Liang B, et al. Association of regular glucosamine use with incident dementia: Evidence from a longitudinal cohort and Mendelian randomization study. BMC Med. 2023;21(1):114. doi: 10.1186/s12916-023-02816-8Li ZH, Gao X, Chung VC, Zhong WF, Fu Q, Lv YB, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: A large prospective cohort study. Ann Rheum Dis. 2020;79(6):829-836. doi: 10.1136/annrheumdis-2020-217176Li ZH, Gao X, Chung VC, Zhong WF, Fu Q, Lv YB, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: A large prospective cohort study. Ann Rheum Dis. 2020;79(6):829-836. doi: 10.1136/annrheumdis-2020-217176

The authors declare that there are no conflicts of interest present.